Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-024 Combination Therapy in Advanced NSCLC
NCT06783647Phase 2Recruiting
- Sponsor
- Leads Biolabs
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of opamtistomig in non-small cell lung cancer (NSCLC), sponsored by Leads Biolabs. Started Jun 2025; status: recruiting.
02
Drugs
opamtistomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06783647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06783647.